Do analysts rate BOLT or QNTM?

Bolt Biotherapeutics presently has a consensus target price of $14.50, indicating a potential upside of 296.17%. Given Bolt Biotherapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Bolt Biotherapeutics is more favorable than Quantum Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bolt Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, KZIA or BOLT?

Novogen has higher earnings, but lower revenue than Bolt Biotherapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 737.00 -$13.41M N/A N/A Bolt Biotherapeutics $4.70M 1.50 -$33.38M -$16.44 N/A

Bolt Biotherapeutics (BOLT) Competitors

$3.66 +0.46 (+14.38%)

As of 08/21/2026 03:57 PM Eastern

Compare

BOLT vs. BRNS, JSPR, QNTM, LGVN, and KZIA

Should you buy Bolt Biotherapeutics stock or one of its competitors? Bolt Biotherapeutics's main competitors and comparable companies include Barinthus Biotherapeutics (BRNS), Jasper Therapeutics (JSPR), Quantum Biopharma (QNTM), Longeveron (LGVN), and Novogen (KZIA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Bolt Biotherapeutics compare to Barinthus Biotherapeutics?

Barinthus Biotherapeutics (NASDAQ:BRNS) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Bolt Biotherapeutics has lower revenue, but higher earnings than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97M	1.70	-$66.43M	-$1.03	N/A
Bolt Biotherapeutics	$4.70M	1.50	-$33.38M	-$16.44	N/A

Barinthus Biotherapeutics has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -611.47%. Barinthus Biotherapeutics' return on equity of -59.15% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%
Bolt Biotherapeutics	-611.47%	-126.23%	-54.70%

25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. 8.5% of Barinthus Biotherapeutics shares are owned by insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Barinthus Biotherapeutics has a beta of -0.39, indicating that its stock price is 139% less volatile than the broader market. Comparatively, Bolt Biotherapeutics has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

In the previous week, Barinthus Biotherapeutics' average media sentiment score of 0.00 equaled Bolt Biotherapeutics'average media sentiment score.

Company	Overall Sentiment
Barinthus Biotherapeutics	Neutral
Bolt Biotherapeutics	Neutral

Barinthus Biotherapeutics presently has a consensus price target of $4.00, indicating a potential upside of 543.40%. Bolt Biotherapeutics has a consensus price target of $14.50, indicating a potential upside of 296.17%. Given Barinthus Biotherapeutics' higher probable upside, equities analysts plainly believe Barinthus Biotherapeutics is more favorable than Bolt Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Barinthus Biotherapeutics and Bolt Biotherapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to Jasper Therapeutics?

Jasper Therapeutics (NASDAQ:JSPR) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Jasper Therapeutics has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -611.47%. Bolt Biotherapeutics' return on equity of -126.23% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-884.17%	-143.83%
Bolt Biotherapeutics	-611.47%	-126.23%	-54.70%

Jasper Therapeutics has a beta of 3.02, suggesting that its share price is 202% more volatile than the broader market. Comparatively, Bolt Biotherapeutics has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market.

In the previous week, Jasper Therapeutics had 8 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 8 mentions for Jasper Therapeutics and 0 mentions for Bolt Biotherapeutics. Jasper Therapeutics' average media sentiment score of 0.04 beat Bolt Biotherapeutics' score of 0.00 indicating that Jasper Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Jasper Therapeutics	Neutral
Bolt Biotherapeutics	Neutral

79.9% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. 2.3% of Jasper Therapeutics shares are owned by company insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bolt Biotherapeutics has higher revenue and earnings than Jasper Therapeutics. Jasper Therapeutics is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A
Bolt Biotherapeutics	$4.70M	1.50	-$33.38M	-$16.44	N/A

Jasper Therapeutics presently has a consensus target price of $8.17, indicating a potential upside of 1,040.60%. Bolt Biotherapeutics has a consensus target price of $14.50, indicating a potential upside of 296.17%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Jasper Therapeutics is more favorable than Bolt Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Jasper Therapeutics beats Bolt Biotherapeutics on 8 of the 15 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to Quantum Biopharma?

Bolt Biotherapeutics (NASDAQ:BOLT) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

Bolt Biotherapeutics has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

Bolt Biotherapeutics presently has a consensus target price of $14.50, indicating a potential upside of 296.17%. Given Bolt Biotherapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Bolt Biotherapeutics is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are held by institutional investors. 9.4% of Bolt Biotherapeutics shares are held by insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Quantum Biopharma has lower revenue, but higher earnings than Bolt Biotherapeutics. Quantum Biopharma is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$4.70M	1.50	-$33.38M	-$16.44	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A

In the previous week, Quantum Biopharma had 5 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 5 mentions for Quantum Biopharma and 0 mentions for Bolt Biotherapeutics. Bolt Biotherapeutics' average media sentiment score of 0.00 beat Quantum Biopharma's score of -0.24 indicating that Bolt Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Bolt Biotherapeutics	Neutral
Quantum Biopharma	Neutral

Quantum Biopharma has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -611.47%. Bolt Biotherapeutics' return on equity of -126.23% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-611.47%	-126.23%	-54.70%
Quantum Biopharma	N/A	-582.23%	-184.20%

Summary

Bolt Biotherapeutics beats Quantum Biopharma on 11 of the 15 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to Longeveron?

Bolt Biotherapeutics (NASDAQ:BOLT) and Longeveron (NASDAQ:LGVN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

Bolt Biotherapeutics has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Longeveron has a beta of -0.31, meaning that its share price is 131% less volatile than the broader market.

Longeveron has lower revenue, but higher earnings than Bolt Biotherapeutics. Longeveron is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$4.70M	1.50	-$33.38M	-$16.44	N/A
Longeveron	$1.20M	21.93	-$22.70M	-$0.99	N/A

86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 9.4% of Bolt Biotherapeutics shares are held by insiders. Comparatively, 7.4% of Longeveron shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Longeveron had 10 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 10 mentions for Longeveron and 0 mentions for Bolt Biotherapeutics. Longeveron's average media sentiment score of 0.04 beat Bolt Biotherapeutics' score of 0.00 indicating that Longeveron is being referred to more favorably in the news media.

Company	Overall Sentiment
Bolt Biotherapeutics	Neutral
Longeveron	Neutral

Bolt Biotherapeutics has a net margin of -611.47% compared to Longeveron's net margin of -1,977.59%. Bolt Biotherapeutics' return on equity of -126.23% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-611.47%	-126.23%	-54.70%
Longeveron	-1,977.59%	-223.19%	-150.20%

Bolt Biotherapeutics currently has a consensus target price of $14.50, suggesting a potential upside of 296.17%. Longeveron has a consensus target price of $8.00, suggesting a potential upside of 846.86%. Given Longeveron's higher possible upside, analysts plainly believe Longeveron is more favorable than Bolt Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Longeveron	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Bolt Biotherapeutics beats Longeveron on 10 of the 16 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to Novogen?

Novogen (NASDAQ:KZIA) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

30.9% of Novogen shares are held by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are held by institutional investors. 1.0% of Novogen shares are held by company insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Novogen currently has a consensus price target of $26.33, suggesting a potential upside of 96.52%. Bolt Biotherapeutics has a consensus price target of $14.50, suggesting a potential upside of 296.17%. Given Bolt Biotherapeutics' higher possible upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Novogen's average media sentiment score of 0.00 equaled Bolt Biotherapeutics'average media sentiment score.

Company	Overall Sentiment
Novogen	Neutral
Bolt Biotherapeutics	Neutral

Novogen has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -611.47%. Novogen's return on equity of 0.00% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Bolt Biotherapeutics	-611.47%	-126.23%	-54.70%

Novogen has higher earnings, but lower revenue than Bolt Biotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	737.00	-$13.41M	N/A	N/A
Bolt Biotherapeutics	$4.70M	1.50	-$33.38M	-$16.44	N/A

Novogen has a beta of 2.16, meaning that its stock price is 116% more volatile than the broader market. Comparatively, Bolt Biotherapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market.

Summary

Novogen beats Bolt Biotherapeutics on 8 of the 12 factors compared between the two stocks.

Get Bolt Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BOLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BOLT vs. The Competition

Export

Metric	Bolt Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.06M	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-0.22	11.62	272.60	24.25
Price / Sales	1.50	1,338.17	618.96	99.78
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	0.56	16.80	13.05	6.20
Net Income	-$33.38M	-$12.50M	$3.47B	$348.59M
7 Day Performance	9.25%	3.29%	2.09%	0.08%
1 Month Performance	-3.94%	8.23%	6.64%	3.88%
1 Year Performance	-28.93%	55.05%	25.02%	16.98%

Bolt Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BOLT Bolt Biotherapeutics	2.9097 of 5 stars	$3.66 +14.4%	$14.50 +296.2%	-28.9%	$7.06M	$4.70M	N/A	90	High Trading Volume
BRNS Barinthus Biotherapeutics	1.9265 of 5 stars	$0.62 +4.5%	$4.00 +545.2%	-47.8%	$24.14M	$14.97M	N/A	107	Short Interest Increase Gap Up High Trading Volume
JSPR Jasper Therapeutics	2.2273 of 5 stars	$0.75 -10.9%	$8.17 +988.9%	-75.6%	$23.58M	N/A	N/A	20	Earnings Report Analyst Forecast Analyst Revision High Trading Volume
QNTM Quantum Biopharma	0.5854 of 5 stars	$3.34 -9.2%	N/A	-81.0%	$23.55M	N/A	N/A	N/A	News Coverage Analyst Upgrade
LGVN Longeveron	1.7148 of 5 stars	$0.79 -4.0%	$8.00 +916.3%	+5.6%	$23.05M	$1.20M	N/A	20	News Coverage Analyst Revision Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BOLT) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bolt Biotherapeutics (BOLT) Competitors

BOLT vs. BRNS, JSPR, QNTM, LGVN, and KZIA

How does Bolt Biotherapeutics compare to Barinthus Biotherapeutics?

Summary

How does Bolt Biotherapeutics compare to Jasper Therapeutics?

Summary

How does Bolt Biotherapeutics compare to Quantum Biopharma?

Summary

How does Bolt Biotherapeutics compare to Longeveron?

Summary

How does Bolt Biotherapeutics compare to Novogen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLT vs. The Competition

Bolt Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bolt Biotherapeutics (BOLT) Competitors

BOLT vs. BRNS, JSPR, QNTM, LGVN, and KZIA

How does Bolt Biotherapeutics compare to Barinthus Biotherapeutics?

Which has stronger earnings and valuation, BRNS or BOLT?

Is BRNS or BOLT more profitable?

Do insiders & institutionals believe in BRNS or BOLT?

Which has more volatility and risk, BRNS or BOLT?

Does the media favor BRNS or BOLT?

Do analysts recommend BRNS or BOLT?

Summary

How does Bolt Biotherapeutics compare to Jasper Therapeutics?

Is JSPR or BOLT more profitable?

Which has more risk and volatility, JSPR or BOLT?

Does the media favor JSPR or BOLT?

Do institutionals and insiders hold more shares of JSPR or BOLT?

Which has better earnings & valuation, JSPR or BOLT?

Do analysts rate JSPR or BOLT?

Summary

How does Bolt Biotherapeutics compare to Quantum Biopharma?

Which has more volatility & risk, BOLT or QNTM?

Do analysts rate BOLT or QNTM?

Do institutionals & insiders hold more shares of BOLT or QNTM?

Which has preferable valuation & earnings, BOLT or QNTM?

Does the media favor BOLT or QNTM?

Is BOLT or QNTM more profitable?

Summary

How does Bolt Biotherapeutics compare to Longeveron?

Which has more volatility & risk, BOLT or LGVN?

Which has better valuation and earnings, BOLT or LGVN?

Do institutionals and insiders have more ownership in BOLT or LGVN?

Does the media refer more to BOLT or LGVN?

Is BOLT or LGVN more profitable?

Do analysts recommend BOLT or LGVN?

Summary

How does Bolt Biotherapeutics compare to Novogen?

Do institutionals & insiders have more ownership in KZIA or BOLT?

Do analysts prefer KZIA or BOLT?

Does the media refer more to KZIA or BOLT?

Is KZIA or BOLT more profitable?

Which has higher earnings & valuation, KZIA or BOLT?

Which has more risk and volatility, KZIA or BOLT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLT vs. The Competition

Bolt Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools